Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval

Shahzad M, Naci H, Wagner AK. Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval. JAMA Intern Med. 2021 Dec 1;181(12):1673-1675. doi: 10.1001/jamainternmed.2021.5989. PMID: 34661616; PMCID: PMC8524351.